Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Developing Point-of-Care Diagnostics for Austere Settings

by Global Biodefense Staff
June 13, 2012

A new report describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most.

Point-of-Care (POC) diagnostics bypass the need for sophisticated laboratory systems by leveraging new technologies to diagnose infectious diseases and other health concerns at the bedside, or “point-of-care”.  Diagnostics account for 2% of the cost of health care, yet can affect 60-70% of treatment decisions. In regions where advanced laboratory services are simply not available or affordable, access to POC technologies is critical in detection and treatment of infectious diseases.

Based on an American Academy of Microbiology symposium convened in September 20122, Bringing the Lab to the Patient: Developing Point-of-Care (POC) Diagnostics for Resource Limited Settings examines the issues at play for successful employment of such technologies.

“POCTs (Point-of-Care technologies) are developed by researchers and engineers and implemented by a separate group of public health professionals at a local level. There are so many variables that can make or break the effectiveness of any test, and so often the scientists and engineers developing the test are not aware of them.” said Keith Klugman, who chaired the symposium. “POCTs that perform well in testing may not function ‘on the ground’ in resource limited areas, where there may not be running water, electricity, or trained personnel to administer the test.”

The report makes several recommendations for POC development prioritization, including improving testing for rapidly fatal diseases, those which respond to treatment only early in their course, and those which have epidemic potential.

Diagnostics which require cerebral-spinal fluid or other invasive biopsies are highlighted as prime candidates for alternative POC diagnostics development, given the risks of those sample collection techniques in austere environments.

Other priorities include replacement of tests that currently need culturing in a laboratory; technologies which simply determine whether disease symptoms are caused by a bacteria or virus; resistance profiles of causative agents; strain differentiation to better inform treatment; and tests which can alert to new mutations  or drug resistance of specific pathogens.

The report goes on to recommend features that should be incorporated in the design of POC technologies to make it more effective in the field, and to identify priorities in utilization of biomarkers for improving diagnostics in this realm.

The full report is available for download here.

Tags: BiomarkersPOC DiagnosticsRuggedized

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC